RAPT Therapeutics (RAPT) Revenue & Revenue Breakdown
RAPT Therapeutics Revenue Highlights
00
RAPT Therapeutics Revenue by Period
RAPT Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | -100.00% |
2022-12-31 | $1.53M | -59.95% |
2021-12-31 | $3.81M | -24.38% |
2020-12-31 | $5.04M | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2017-12-31 | - | - |
RAPT Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $5.29M | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | -100.00% |
2022-12-31 | $641.00K | 100.00% |
2022-09-30 | - | -100.00% |
2022-06-30 | $886.00K | 38.22% |
2022-03-31 | $641.00K | -15.21% |
2021-12-31 | $756.00K | -21.74% |
2021-09-30 | $966.00K | 11.16% |
2021-06-30 | $869.00K | -28.89% |
2021-03-31 | $1.22M | -6.14% |
2020-12-31 | $1.30M | -14.79% |
2020-09-30 | $1.53M | 19.66% |
2020-06-30 | $1.28M | 36.58% |
2020-03-31 | $935.00K | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | - |
RAPT Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
ARVN | Arvinas | $78.50M | $102.40M |
RLAY | Relay Therapeutics | $25.55M | - |
HOWL | Werewolf Therapeutics | $19.94M | $1.14M |
IKNA | Ikena Oncology | $9.16M | - |
STOK | Stoke Therapeutics | $8.78M | $4.89M |
MOLN | Molecular Partners | $7.04M | $2.74M |
HCWB | HCW Biologics | $2.84M | $426.42K |
PLRX | Pliant Therapeutics | $1.58M | - |
ANEB | Anebulo Pharmaceuticals | - | - |
DSGN | Design Therapeutics | - | - |
RAPT | RAPT Therapeutics | - | - |
BDTX | Black Diamond Therapeutics | - | - |
ANTX | AN2 Therapeutics | - | - |
PHVS | Pharvaris | - | - |
CNTB | Connect Biopharma | - | - |
PMVP | PMV Pharmaceuticals | - | - |
MLYS | Mineralys Therapeutics | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
PEPG | PepGen | - | - |
TYRA | Tyra Biosciences | - | - |
XLO | Xilio Therapeutics | - | $2.36M |